Table 4.
Reports on the synergistic effects of combined phage and antibiotic therapy.
| Study | Target Bacteria | Phage (Dosages) | Antibiotic (Dosages) | References | |
|---|---|---|---|---|---|
| 1 | Racenis et al., 2023 | Multidrug-resistant P. aeruginosa | Phages PNM and PT07 (Titer of 107 PFU/mL) | Ceftazidime/Avibactam (2.5 g) and Amikacin (750 mg) | [133] |
| 2 | Kebriaei et al., 2023 | Methicillin-resistant S. aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) | Phages Intesti13, Sb-1, and Romulus (107 PFU/well) | Daptomycin, vancomycin, and ceftaroline at 0.5× MBIC or 1× MBIC | [105] |
| 3 | Altamirano et al., 2022 | A. baumannii AB900 | Phages øFG02 (range: 102–108 PFU/mL) | Ceftazidime (range: 1–512 mg/mL) | [135] |
| 4 | Cano et al., 2021 | K. pneumoniae complex KpJH46 | Phage KpJH46Φ2(6.3 × 1010 phages in 50 mL for a total of 40 doses) | Minocycline, 100 mg | [136] |
| 5 | Morales et al., 2020 | S. aureus | Three Myoviridae bacteriophages AB-SA01 (109 PFU/mL) | lucloxacillin, Cefazolin, Vancomycin, Ciprofloxacin, Rifampicin | [137] |
| 6 | Jault et al., 2019 | P. aeruginosa | cocktail of 12 natural lytic anti-P. aeruginosa bacteriophages (PP1131; 1 × 106 PFU]/mL) | 1% sulfadiazine silver emulsion cream | [138] |
| 7 | Osman et al., 2023 | MDR A. baumannii | Multiple phage cocktails (C2P24, AC4, C2P21, and C1P12) | Minocycline | [139] |